FeesSafety
Pluang+

Investors seek clear Fed strategy as Chair Warsh addresses inflation and rate hikes.

Market News
24 Oct 2026
Market Watch
View Source
Neutral
Investors seek clear Fed strategy as Chair Warsh addresses inflation and rate hikes.

At the Federal Reserve's recent meeting, the key focus for investors was not just the interest rate decision but how Chairman Kevin Warsh communicates the Fed's strategy. With inflation running above the 2% target for over five years, investors and economists want clarity on whether recent inflation data will change the Fed's approach and how future rate hikes will be timed and paced. Warsh's press conference is crucial for signaling the Fed's plan to control inflation moving forward.

The Federal Reserve's communication strategy on inflation and rate hikes is under scrutiny as inflation remains above 2% for over five years. For readers following the Financials sector, here is Pluang's market snapshot as of Oct 24, 2026 16:41 WIB: out of 142 priced US Financials stocks, 21 rose and 119 fell. Notable movers include FLG (Flagstar Bank NA) down 9.42% at USD 10.38 with 100% buy order activity, BTBT (Bit Digital Inc) down 6.85% at USD 0.84 with 81% sell order activity, and SEZL (Sezzle Inc) down 5.15% at USD 132.12 with 99% sell order activity.

More News

Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...

Company Fundamentals
Bullish
52 minutes ago
Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...

Company Fundamentals
Bullish
52 minutes ago
AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker has introduced a comprehensive Business Class Flight Routes Guide to help travelers from the US explore premium flight options to 15 major international destinations across Asia, Europe, Africa, and Australia. The guide covers airlines, ...

Others
Neutral
3 hours ago
Trump adjusts Canada tariffs days before midterms, adding more items than removing.

Trump adjusts Canada tariffs days before midterms, adding more items than removing.

President Trump signed a proclamation on October 23, 2026, reshuffling which Canadian goods face his 50% tariffs, removing items like plywood and packing crates but adding others such as carpets and vinyl flooring. The broad tariffs on about $20 bill...

Market News
Neutral
4 hours ago
Injective CEO meets US regulators to push for clearer rules on tokenized assets and onchain finance.

Injective CEO meets US regulators to push for clearer rules on tokenized assets and onchain finance.

Injective CEO Eric Chen met with officials from the White House, SEC, and CFTC in October 2026 to discuss advancing regulated onchain finance and tokenization of real-world assets (RWAs) in the US. Injective, registered as a transfer agent by the SEC...

Market News
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App